Amytrx Therapeutics

About Amytrx Therapeutics

Amytrx Therapeutics is a biopharmaceutical company that advances the next generation of new anti-inflammatory peptide therapies for patients with chronic inflammatory diseases. The company's AMTX-100 is bioengineered using human protein sequences that modulate the immune system by a natural process. Amytrx Therapeutics was founded in 2014 by Matthew A. Gonda and is based in Nashville, Tennessee.

Industries

Investors in Amytrx Therapeutics

No investors recorded yet.